이 에피소드에 관해
The world doesn't have a shortage of promising medical discoveries. The real challenge is turning those discoveries into safe, effective, accessible treatments. What separates a breakthrough idea from a successful therapy? How could AI change the economics of drug development? And can regenerative medicine move healthcare beyond managing disease toward restoring damaged tissue? Today, we're tackling these questions with pharmaceutical executive and biotech entrepreneur Dr. Stella Vnook.
Dr. Stella Vnook is a pharmaceutical and biotechnology executive, serial entrepreneur, and healthcare innovator with more than 25 years of experience spanning drug development, commercialization, strategic partnerships, and company building.
A Temple University School of Pharmacy alumna, Dr. Vnook is being recognized with the university's Pharmaceutical Innovation Award as Temple celebrates its 125th anniversary - an honor recognizing her contributions to healthcare innovation.
Over the course of her career, Dr. Vnook spent nearly 14 years at Merck in roles spanning pharmaceutical marketing, managed markets, and corporate strategy, before moving into global pharmaceutical technology and commercialization leadership at Catalent. She subsequently took on executive leadership and company-building roles across a range of biotechnology ventures, including oncology, immunotherapy, and advanced drug-delivery technologies.
Today, Dr. Vnook is the founding and managing partner of AVIVA Ventures, a life-sciences venture studio integrating AI into the process of building and transforming biotech and pharmaceutical companies. She is also the founder, president, and CEO of Oral BioLife ( https://oralbiolife.com/ ), which is developing regenerative technology intended to stimulate bone regeneration in periodontal disease, and she has served as CEO of companies working on advanced cell therapies and drug-delivery platforms.
Dr. Vnook's experience spans the scientific, operational, financial, and commercial sides of healthcare innovation - including fundraising, strategic licensing, market access, and the challenge of bringing new technologies from early research toward clinical and commercial application.
Today, we'll discuss what it takes to build successful biotech companies, where regenerative medicine could take us, how AI might change the business of drug development, and what it will take to ensure that scientific breakthroughs ultimately translate into better outcomes for patients.
#StellaVnook #OralBioLife #RegenerativeMedicine #BoneRegeneration #Biotechnology #DrugDevelopment #PharmaceuticalInnovation #AIinHealthcare #DrugDiscovery #Biotech #PrecisionMedicine #HealthcareInnovation #PeriodontalDisease #DentalHealth #ProgressPotentialAndPossibilities
